Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ALZN002
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Recipient : Alzamend Neuro
Deal Size : Inapplicable
Deal Type : Inapplicable
Study in Subjects With Mild-to-Moderate Alzheimer's Dementia
Details : ALZN002 is a Vaccine drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
April 28, 2023
Lead Product(s) : ALZN002
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Recipient : Alzamend Neuro
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ALZN002
Therapeutic Area : Neurology
Study Phase : IND Enabling
Recipient : Alzamend Neuro
Deal Size : Undisclosed
Deal Type : Partnership
Details : ALZN002 is a proprietary active immunotherapy product. It consists of autologous DCs, which are activated WBCs taken from each individual patient that are then engineered outside of the body to attack Alzheimer’s-related amyloid-beta proteins.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
January 04, 2023
Lead Product(s) : ALZN002
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Recipient : Alzamend Neuro
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Laromestrocel
Therapeutic Area : Neurology
Study Phase : Phase II
Recipient : Longeveron
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of adult donors. Longeveron is advancing Lomecel-B through clinical trials in 3 indications: Hypoplastic Left Heart Syndrome, Alzheimer’s Disease, and...
Product Name : Lomecel-B
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
November 10, 2022
Lead Product(s) : Laromestrocel
Therapeutic Area : Neurology
Highest Development Status : Phase II
Recipient : Longeveron
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Minocycline Hydrochloride,Ethanol,Edetate Calcium Disodium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Citius Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Citius Pharmaceuticals to Accelerate Phase 3 Mino-Lok Trial by Expanding Trial Sites Internationally
Details : Mino-Lok (minocycline) is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs).
Product Name : Mino-Lok
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 06, 2022
Lead Product(s) : Minocycline Hydrochloride,Ethanol,Edetate Calcium Disodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Citius Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Allogeneic Umbilical Cord Mesenchymal Stem Cell
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : Therapeutic Solutions
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : JadiCell (mesenchymal stem cells), was shown to be 100% effective in saving the lives of COVID-19 patients under age of 85 in a double-blind, randomized, placebo controlled clinical trial with patients in the ICU on a ventilator.
Product Name : JadiCell
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
May 02, 2022
Lead Product(s) : Allogeneic Umbilical Cord Mesenchymal Stem Cell
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Therapeutic Solutions
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Allogeneic Umbilical Cord Mesenchymal Stem Cell
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : Therapeutic Solutions
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The unprecedented results from JadiCells allowed for 100% patient survival at one month in subjects treated who were less than 85 years old, and 91% survival in subjects of all ages, compared to 42% survival in the control group.
Product Name : JadiCell
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
March 28, 2022
Lead Product(s) : Allogeneic Umbilical Cord Mesenchymal Stem Cell
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Therapeutic Solutions
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Allogeneic Mesenchymal Stem Cell
Therapeutic Area : Neurology
Study Phase : Phase II
Recipient : Longeveron
Deal Size : Inapplicable
Deal Type : Inapplicable
Lomecel-B Effects on Alzheimer's Disease
Details : Allogeneic Mesenchymal Stem Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
February 10, 2022
Lead Product(s) : Allogeneic Mesenchymal Stem Cell
Therapeutic Area : Neurology
Highest Development Status : Phase II
Recipient : Longeveron
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rifaximin
Therapeutic Area : Dermatology
Study Phase : Phase II
Recipient : Alfasigma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rifaximin is a Antibiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Rosacea.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
December 09, 2021
Lead Product(s) : Rifaximin
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Recipient : Alfasigma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Laromestrocel
Therapeutic Area : Neurology
Study Phase : Phase I
Recipient : Longeveron
Deal Size : Inapplicable
Deal Type : Inapplicable
Longeveron Selects Clinical Research Organization for Phase 2 Alzheimer’s Disease Trial
Details : LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors.
Product Name : Lomecel-B
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
November 05, 2021
Lead Product(s) : Laromestrocel
Therapeutic Area : Neurology
Highest Development Status : Phase I
Recipient : Longeveron
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Allogeneic Mesenchymal Bone Marrow Cell
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : Stemedica Cell Technologies
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19
Details : Allogeneic Mesenchymal Bone Marrow Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
March 03, 2021
Lead Product(s) : Allogeneic Mesenchymal Bone Marrow Cell
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : Stemedica Cell Technologies
Deal Size : Inapplicable
Deal Type : Inapplicable